186 results about "Atheromatosis" patented technology

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention discloses an MKP7 targeted bionic nanoparticle preparation as well as a preparation method and application thereof. The MKP7 targeted bionic nanoparticle preparation is a bionic nanoparticle siMKP7 (at) NP-M-pHLIP, wherein the bionic nanoparticle siMKP7 (at) NP-M-pHLIP is coated with a macrophage membrane modified by pHLIP and is loaded with siMKP7. According to the preparation, a PLGA-PEI copolymer is used as a carrier core to wrap siMKP7, an outer layer is coated with a macrophage membrane, the surface of the membrane is modified with pHLIP targeting peptide, and spherical nanoparticles with bionic camouflage and pH sensitive targeting delivery functions are constructed. In-vitro experiments show that the nanoparticles can be effectively ingested by macrophages, and macrophage lipid deposition induced by ox-LDL is remarkably inhibited; in-vivo experiments prove that the preparation can be delivered to atherosclerotic plaque parts in a targeted manner, and by inhibiting expression of MKP7 in macrophages, the carotid plaque area is effectively reduced, the serum inflammatory factor level is reduced, and the blood lipid metabolism is regulated, so that development of atherosclerosis is inhibited, and the curative effect of atherosclerosis is improved. A high-efficiency and low-toxicity nucleic acid drug delivery system is provided for treatment of atherosclerosis.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention provides a white flower salvia miltiorrhiza composition and application thereof in medicines for preventing and treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. According to the technical scheme, the composition is characterized by comprising 3-5 parts of white flower salvia miltiorrhiza root slices, 1-2 parts of white flower salvia miltiorrhiza dried leaves and 1-2 parts of white flower salvia miltiorrhiza extract. Mixing the white flower salvia miltiorrhiza leaf powder with a malic acid aqueous solution, carrying out ultrasonic treatment, filtering, and carrying out alcohol precipitation on filtrate to obtain an alcohol precipitate; extracting the white flower salvia miltiorrhiza root powder by using supercritical carbon dioxide to obtain a supercritical extract; mixing the alcohol precipitate and the supercritical extract according to the weight ratio of (7-9): (1-3) to obtain a white flower salvia miltiorrhiza extract; the alcohol used in the alcohol precipitation is methanol; methyl acetate is used as an entrainer in the supercritical carbon dioxide extraction. The white flower salvia miltiorrhiza composition provided by the invention has the beneficial technical effect of remarkably improving atherosclerosis.

The application relates to the technical field of organic fluorescent probes, and particularly discloses a lipid droplet and hypochlorous acid sequence response type fluorescent probe, a structural formula of which is as shown in the figure; wherein R is a cyano group, a benzothiazole group, a benzimidazole group, an amido group, an ethoxycarbonyl group or an acetyl group. The precise imaging lipid droplet and hypochlorous acid sequence response fluorescent probe of the application takes a phenothiazine-coumarin dye support as a matrix, utilizes a double trifluoromethyl benzyl group as a lipid droplet targeting group, adjusts the dye emission wavelength by introducing different electron-withdrawing groups, synthesizes a series of probes, and realizes high-targeting sequence imaging of lipid droplets and hypochlorous acid in atherosclerotic plaques.

The invention discloses a traditional Chinese medicine composition with effects of reducing blood fat and resisting carotid atherosclerotic plaque and a preparation method of the traditional Chinese medicine composition. The composition is innovatively cut by taking eight-treasure soup as a basic framework, and comprises American ginseng, astragalus membranaceus, lucid ganoderma, saffron crocus extract, saussurea involucrata culture, donkey-hide gelatin, angelica sinensis, prepared rehmannia root, peach kernel, hawthorn, semen cassiae, lotus leaf, mulberry leaf, dandelion, hovenia dulcis thunb, kudzu vine root, radix polygonati officinalis, poria cocos, coix seed, orange peel, fructus amomi and honey-fried licorice root. American ginseng is used for replacing ginseng, radix astragali is used for reinforcing qi tonifying, saffron crocus, peach kernels, hawthorn fruits and the like are matched for reinforcing blood circulation promoting and blood stasis removing, semen cassiae, lotus leaves and other medicine groups for clearing heat, reducing phlegm and descending turbidity are added, and meanwhile fructus amomi and orange peel are used for strengthening the spleen and regulating qi. The traditional Chinese medicine composition has the effects of supporting the healthy energy and treating phlegm and blood stasis on the pathogenesis of qi-blood deficiency and phlegm and blood stasis, and has a synergistic enhancement effect on the aspects of reducing blood fat and inhibiting atherosclerotic plaque.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.

This invention discloses a highly active and safe refined rubber seed oil, its preparation method, and its applications. The substance is obtained from crude rubber seed oil through alkali neutralization, natural sedimentation, centrifugation, adsorption filtration, and distillation. This substance not only exhibits high activity—superior to crude rubber seed oil in inhibiting atherosclerotic plaque formation and promoting plaque regression—but also demonstrates high safety, meeting national food safety standards. This substance can be applied to health foods, foods for special medical purposes, and other special foods for the health improvement and promotion of individuals with atherosclerosis.

The invention discloses a nucleic acid-loaded metal polyphenol nano-drug for targeting macrophages as well as a preparation method and application thereof, the nano-drug takes a metal polyphenol network formed by self-assembly of cerium ions and kaempferol through coordinate bonds as a core carrier, therapeutic nucleic acid is loaded in the nano-drug, and a hyaluronic acid targeting layer is coated on the outer layer of the nano-drug. According to the invention, Ce, Kae and DNA are mixed and self-assembled to form a Ce-Kae-DNA core, and then HA is coated through electrostatic interaction. The nano-drug can deliver nucleic acid to macrophages in a targeted mode, cholesterol excretion is remarkably promoted, meanwhile, reactive oxygen species (ROS) are removed, the inflammation microenvironment is adjusted, and the nano-drug has important application prospects in preparation of drugs for treating inflammation-related diseases such as atherosclerosis.

The present application relates to the technical field of animal model construction, and specifically discloses a method for constructing an atherosclerotic plaque thrombosis model. ‑ / ‑ The method comprises the following steps: 1) selecting an ApoE The method provided by the present application is simple in operation, high in repeatability, and can induce atherosclerotic plaque thrombosis under the stimulation of a low-dose LPS, and can obtain a thrombosis rate comparable to that of the prior art, and can be closer to the formation of atherosclerotic thrombosis related to clinical endotoxemia, and better simulate the clinical pathological process.

Disclosed is an intravascular calcification lesion ultrasonic-powered rotary grinding device. The technical problem to be solved is to improve the safety of surgeries and reduce costs. In the present invention, a rotary grinding head is provided, and from the proximal end to the distal end, an ultrasonic motor system, a first-order transmission acceleration mechanism, a second-order transmission acceleration mechanism, and a rotary grinding head, which are connected in sequence, are provided. The rotary grinding head has a rotating speed of 60,000 rad / min to 120,000 rad / min. Compared with the prior art, the present invention adopts an ultrasonic motor to convert electrical energy into rotational mechanical energy, to drive the transmission acceleration mechanism to achieve the rotation of the rotary grinding head, and is used for dredging or improving severely narrow and severely calcified or fibrotic atherosclerotic lesions in coronary arteries. The rotary grinding head has low transmission noise in high-speed rotation, reducing the frictional heat retained in a human body caused by rotary grinding, reducing the amount of cooling and lubricating solution input into the human body, and reducing the metabolic burden on human kidneys. The present invention has safety, reliability, a simple structure, and low costs.

The invention relates to the technical field of diabetic hypoglycemia, and discloses a diabetic hypoglycemia response induced vascular injury biomarker which is a combination of high-sensitivity C reactive protein, 8-isoprostaglandin F2alpha, von willebrand factor, free fatty acid and D-dimer. The invention further discloses application of the diabetic hypoglycemic response induced vascular injury biomarker in preparation of a reagent for early auxiliary diagnosis of diabetic hypoglycemic response induced vascular injury. According to the invention, a combination of high-sensitivity C-reactive protein, 8-isoprostaglandin F2alpha, von willebrand factor, free fatty acid and D-dimer is used as a vascular injury biomarker induced by diabetes mellitus hypoglycemia response; acute vascular dysfunction, cardiovascular system injury, microvascular complications and atherosclerosis can be effectively diagnosed, diabetic vasculopathy can be found at an early stage, disease progression can be predicted, and clinical treatment can be guided; the sensitivity and the specificity are high.

To provide novel constructs for chimeric antigen receptors.SOLUTION: The present disclosure relates to immune cells comprising chimeric antigen receptors (CARs) and methods of using immune cells comprising CARs. Although immunotherapy is being investigated for many diseases and disorders, including cancer, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), systemic amyloidosis, prion diseases, heart disease, atherosclerosis, fibrosis, there is still a need to address the functional limitations encountered so far.SELECTED DRAWING: None

This invention discloses a gene editing system for constructing a porcine nuclear transplantation donor cell model of atherosclerosis with double gene mutations in AF and its applications. The invention provides a kit comprising plasmid pKG-U6gRNA (APOE-E2-gRNA2), a target sequence binding region as shown in nucleotides 3-22 of SEQ ID NO: 25 (FBN1-gRNA4), a target sequence binding region as shown in nucleotides 3-22 of SEQ ID NO: 26 (FBN1-gRNA6), and FBN1-mutant-ss163 as shown in SEQ ID NO: 27. The kit is used for: preparing recombinant cells; preparing porcine atherosclerosis models; preparing atherosclerosis cell models, atherosclerosis tissue models, or atherosclerosis organ models. The plasmid pKG-U6gRNA (APOE-E2-gRNA2) is transcribed to obtain sgRNA with a target sequence binding region as shown in nucleotides 1-20 of SEQ ID NO: 11. APOE‑E2‑gRNA2 This invention lays the foundation for developing pig models of atherosclerosis through somatic cell nuclear transfer animal cloning technology.

The application discloses a kind of magnetic nanoparticles for atherosclerosis diagnosis and treatment.It is core-shell structure, the inner core is Fe₃O₄ magnetic nano material, shell is the drug-loading layer of biodegradable polymer material, the drug-loading layer is encapsulated with analog movement polypeptide K271la, and the surface of nano particle is covalently coupled with CD36 targeting antibody.Its preparation method mainly includes: by complex emulsification-solvent volatilization method, Fe₃O₄ nanoparticle and K271la polypeptide are co-encapsulated in one step, form nanoparticle, and then CD36 antibody is modified on the surface of particle by chemical coupling.The nanoparticle of the application has the ability of active targeting (CD36 antibody) and passive targeting (magnetic response), can be efficiently enriched in plaque, and deliver therapeutic polypeptide to macrophages, activate lipophagy to remove lipid;It can be used as magnetic resonance imaging contrast agent, realizes diagnosis and treatment integration, and provides a new strategy for solving the problem of low efficiency of atherosclerosis targeted therapy and lack of effective monitoring means.

The application discloses application of CCL3-AS1 in regulating stability of carotid artery plaque, overexpression of CCL3-AS1 induces inflammatory activity of macrophages and secretion of MMP9, promotes plaque rupture and thrombosis; on the contrary, knockdown of CCL3-AS1 inhibits inflammatory activity of macrophages and secretion of MMP9, reduces plaque rupture and thrombosis; in addition, the application also discloses that CCL3-AS1 enhances MMP9 mRNA stability by combining with hnRNP-K, thereby increasing MMP9 expression and secretion and degrading fibrous cap collagen. The application discloses important role of CCL3-AS1 in stability of carotid artery plaque and a molecular mechanism, provides a new diagnostic marker and a treatment target, not only provides a new direction for research on atherosclerosis related diseases, but also provides a new tool and a means for clinical diagnosis and treatment.

The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.

The invention discloses an application of a bacterium in preparation of an anti-atherosclerosis drug, explores a potential effect of Agathobacter recalcalis in prevention and treatment of atherosclerosis diseases, and is beneficial to screening of safer and more effective drugs and prevention and treatment means to improve atherosclerosis. The bacterial strain is Agathobacter rectalis, and the bacterial strain is a bacterial strain.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The imaging apparatus configured to assess and quantify motion associated with an object and, in a specific case of an eye—retinal vascular anatomy and hemodynamics and generate substantially contrast-free maps of retinal blood flow over a wide field-of-view at up to 590 fps and under short exposure durations (>50 μs), is applicable for diagnosis, study, and management of neurodegenerative conditions (i.e. mild cognitive impairment and Alzheimer's disease) and systemic cardiovascular diseases (i.e. athero- and arteriosclerosis, coronary artery occlusion, and hypertension). The apparatus employs a) a set of apertures substantially blocking light, delivered from a source of light to an illumination arm of the apparatus, from impinging onto an axial point of the front surface of the lens of the illumination arm, and b) polarization gating between the illumination and light-collecting arms of the apparatus. In one implementation, the apparatus is configured to allow for irradiation of the object with an optical field a degree of coherence and / or spectral content of which are varied delivered through the same optical train including the set of apertures.

The invention relates to an application of ridecevir in preparation of a medicine for preventing and treating atherosclerosis. The application of the ridecevir in preparation of the medicine for preventing and treating the atherosclerosis comprises one or more of the following effects: (1) the ridecevir has an inhibiting effect on formation of atherosclerotic plaques; (2) the ridecevir plays a role in inhibiting the activation of vascular endothelium; (3) the ridecevir plays a role in reducing mRNA (messenger Ribonucleic Acid) and protein expression level of VCAM-1 and ICAM-1 mediated by ox-LDL (Lipoprotein Dehydrogenase Lipoprotein); (4) the ridecevir plays a role in reducing the immunofluorescence expression of ox-LDL mediated endothelial cells such as VCAM-1 and ICAM-1; and (5) reducing the adhesion of the ox-LDL mediated THP1 cell on the surface of the endothelial cell by the ridecevir. The invention provides new application of the ridecevir, namely application of the ridecevir or pharmaceutically acceptable salts, esters and hydrates of the ridecevir in preparation of medicines for preventing and treating atherosclerosis diseases. The invention provides an effective novel potential alternative drug for preventing and treating atherosclerosis, expands the adaptation of the ridegravir, and improves the application potential and market prospect of the ridegravir.

The application discloses a prediction model of the risk of atherosclerosis of a type 2 diabetes patient and a construction method thereof, and the construction method comprises the following steps: obtaining general information, serum biochemical indexes and a brachial-ankle pulse wave velocity of the type 2 diabetes patient; calculating a ratio of visceral fat area and subcutaneous fat area of the patient; comparing the correlation of the general information and the serum biochemical indexes by using a single factor variance and a chi-square test method to obtain variables with statistical differences; determining influencing factors of the type 2 diabetes patient combined with atherosclerosis by using Spearman correlation analysis and multivariate logistic regression analysis; and constructing a logistic regression model: Logit (H) =-4.647+1.013*V / S+0.099*age-0.527*smoking+0.67*Hypertension-0.007*Cr, namely, the prediction model. The prediction model has good prediction performance and high clinical application value.

The application discloses a traditional Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Radix Rehmanniae Preparata 12-15 parts, Cistanche 9-12 parts, Radix Astragali 12-15 parts, Cyperus rotundus 6-9 parts, Salvia miltiorrhiza 15-30 parts and safflower 6-9 parts. In addition, the application also relates to a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition has obvious effects of treating atherosclerosis, reducing homocysteine and blood lipid levels, improving patient symptoms and reducing atherosclerosis-related complications.

Immunogenic peptide fragments of metalloprotease ADAMTS-7 including a first short peptide, which is any one of the followings: a short peptide having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing. The description includes uses of conjugates containing the above short peptides and vaccines containing the conjugates. The vaccines containing the short peptides can remarkably inhibit the intimal neogenesis in the vascular restenosis mouse models and the occurrence of atherosclerosis in high-fat-fed mice, and can be used for the prevention or treatment of atherosclerosis and / or vascular restenosis.

This invention belongs to the field of traditional Chinese medicine technology, and discloses a kidney-tonifying and turbidity-resolving traditional Chinese medicine compound, its preparation method, and its anti-atherosclerotic application. The effective components of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound, by mass, consist of 15 parts Rehmannia glutinosa (processed), 15 parts Astragalus membranaceus (raw), 9 parts Cistanche deserticola, 10 parts Nelumbo nucifera (lotus leaf), 20 parts Gynostemma pentaphyllum, 12 parts Crataegus pinnatifida, and 6 parts Citrus reticulata (dried tangerine peel). The preparation method of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound is simple, without any additives, and has strong pharmacological compatibility. The anti-atherosclerotic application of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound includes: including observation cases, grouping, measuring the CIMT value and plaque area of ​​the included cases, data processing, and result analysis. This invention's kidney-tonifying and turbidity-resolving traditional Chinese medicine intervention can reduce the CIMT value and carotid plaque area in patients with atherosclerosis, and has a significant anti-atherosclerotic effect.